|
Legal Entity
|
Jurisdiction
|
Relationship with the Company
|
|
I.M.C. Holdings Ltd. (“IMC Holdings”)
|
Israel
|
Wholly-owned subsidiary
|
|
I.M.C. Pharma Ltd. (“IMC Pharma”)
|
Israel
|
Wholly-owned subsidiary of IMC Holdings
|
|
Focus Medical Herbs Ltd. (“Focus")(1)
|
Israel
|
Wholly-owned subsidiary of IMC Holdings
|
|
R.A. Yarok Pharm Ltd. (“Pharm Yarok”)
|
Israel
|
Wholly-owned subsidiary of IMC Holdings
|
|
Rosen High Way Ltd. (“Rosen High
Way”)
|
Israel
|
Wholly-owned subsidiary of IMC Holdings
|
|
Rivoly Trading and Marketing Ltd. d/b/a
Vironna Pharm (“Vironna”)
|
Israel
|
Subsidiary of IMC Holdings
|
|
Adjupharm GmbH (“Adjupharm”)
|
Germany
|
Subsidiary of IMC Holdings
|
|
Xinteza API Ltd (“Xinteza”)
|
Israel
|
Subsidiary of IMC Holdings
|
|
Shiran Societe Anonyme (“Greece”)
|
Greece
|
Subsidiary of IMC Holdings
|
|
IM Cannabis Holding NL B.V Netherlands (“IMC Holdings NL”)
|
Netherlands
|
Wholly-owned subsidiary of IMC Holdings
|
|
(1)
|
Effective February 26, 2024, IMC Holdings exercised its option to acquire a 74% ownership stake in Focus, and effective May
26, 2025, IMC Holdings acquired the remaining 26% from Ewave Group Ltd.
|